Sanofi Anticipates the Approval of its COVID-19 Vaccine by First Half of 2021

 Sanofi Anticipates the Approval of its COVID-19 Vaccine by First Half of 2021

Sanofi Anticipates the Approval of its COVID-19 Vaccine by First Half of 2021

Shots:

  • Sanofi divulges in its virtual R&D day that the company is anticipating initiation of P-I/II study evaluating the recombinant protein-based​ vaccine candidate (baculovirus), developing in collaboration with GSK while expecting the complete approval in H1’20
  • Sanofi also highlights capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
  • Additionally, Sanofi reveals the clinical status of Venglustat for which P-II/III clinical trial in Gaucher disease type 3 is ongoing, P-III study in Tay-Sachs disease, a type of GM-2 gangliosidoses, was initiated at the beginning of 2020 while P-III study in Fabry diseases to be initiated in 2021

Click here to read full press release/ article | Ref: Sanofi | Image: Pharmaceutical Technology

Related News: Sanofi and GSK Collaborate to Develop Adjuvanted COVID-19 Vaccine

Sanofi’s COVID-19 Vaccine to be Available Globally

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post